On Oct 30, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $4 to $26.
J.P. Morgan analyst Anupam Rama maintains with a hold rating.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $10.
Mizuho Securities analyst Uy Ear maintains with a hold rating.
Needham analyst Ami Fadia maintains with a hold rating.
RBC Capital analyst Brian Abrahams maintains with a sell rating, and maintains the target price at $4.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics has been observed to report third quarter results with notable total revenue, operating expenses, and a cash position that is predicted to extend the company's financial runway into 2026. The disappointing outcome of the SAGE-718 Phase 2 LIGHTWAVE study for patients with Alzheimer's Disease Mild Cognitive Impairment has led to a strategic shift to focus on the development of Zurzuvae and the potential of dalzanemdor for Huntington's Disease Mild Cognitive Impairment, with Phase 2 DIMENSION results anticipated by the end of 2024. Additionally, there is an expectation of relevant updates from Biogen regarding its third quarter in 2024.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月30日，多家華爾街大行更新了$Sage Therapeutics (SAGE.US)$的評級，目標價介於4美元至26美元。
摩根大通分析師Anupam Rama維持持有評級。
TD Cowen分析師Ritu Baral維持持有評級，維持目標價10美元。
瑞穗證券分析師Uy Ear維持持有評級。
Needham分析師Ami Fadia維持持有評級。
加皇資本市場分析師Brian Abrahams維持賣出評級，維持目標價4美元。
此外，綜合報道，$Sage Therapeutics (SAGE.US)$近期主要分析師觀點如下：
以下爲今日9位分析師對$Sage Therapeutics (SAGE.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
